Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 18 | 2018 | 232 | 3.320 |
Why?
|
| Heroin | 16 | 2011 | 21 | 2.740 |
Why?
|
| Rats | 46 | 2020 | 1592 | 2.150 |
Why?
|
| Rats, Inbred F344 | 31 | 2018 | 133 | 1.930 |
Why?
|
| Cocaine | 15 | 2023 | 256 | 1.820 |
Why?
|
| Conditioning, Operant | 7 | 2014 | 88 | 1.730 |
Why?
|
| Self Administration | 24 | 2020 | 297 | 1.660 |
Why?
|
| Spinal Nerves | 9 | 2020 | 65 | 1.590 |
Why?
|
| Receptors, Opioid, mu | 7 | 2015 | 31 | 1.540 |
Why?
|
| Animals | 55 | 2024 | 7510 | 1.480 |
Why?
|
| Brain | 10 | 2020 | 948 | 1.430 |
Why?
|
| Reaction Time | 4 | 2018 | 117 | 1.350 |
Why?
|
| Hyperalgesia | 9 | 2020 | 78 | 1.320 |
Why?
|
| Pain Measurement | 9 | 2018 | 349 | 1.250 |
Why?
|
| Choice Behavior | 3 | 2020 | 86 | 1.240 |
Why?
|
| Naltrexone | 9 | 2011 | 18 | 1.230 |
Why?
|
| Attention | 3 | 2018 | 83 | 1.220 |
Why?
|
| Pain, Postoperative | 7 | 2018 | 178 | 1.210 |
Why?
|
| Behavior, Animal | 9 | 2017 | 249 | 1.130 |
Why?
|
| Nucleus Accumbens | 10 | 2018 | 94 | 1.080 |
Why?
|
| Photic Stimulation | 2 | 2017 | 158 | 1.030 |
Why?
|
| Narcotic Antagonists | 8 | 2011 | 40 | 0.990 |
Why?
|
| Pain | 6 | 2023 | 287 | 0.970 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2018 | 629 | 0.960 |
Why?
|
| Morphine | 7 | 2012 | 44 | 0.940 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 6 | 2015 | 20 | 0.920 |
Why?
|
| Male | 50 | 2024 | 19202 | 0.860 |
Why?
|
| Neuralgia | 4 | 2019 | 48 | 0.850 |
Why?
|
| Electric Stimulation | 3 | 2012 | 104 | 0.850 |
Why?
|
| Reward | 2 | 2011 | 64 | 0.740 |
Why?
|
| Neurons | 3 | 2018 | 407 | 0.730 |
Why?
|
| Heroin Dependence | 3 | 2007 | 5 | 0.720 |
Why?
|
| Pain Threshold | 7 | 2020 | 92 | 0.710 |
Why?
|
| Self Stimulation | 3 | 2014 | 3 | 0.670 |
Why?
|
| Ventral Tegmental Area | 5 | 2018 | 31 | 0.660 |
Why?
|
| Narcotics | 5 | 2007 | 16 | 0.650 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2016 | 24 | 0.650 |
Why?
|
| Injections, Spinal | 6 | 2011 | 108 | 0.640 |
Why?
|
| Cues | 2 | 2017 | 68 | 0.620 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 71 | 0.610 |
Why?
|
| Abdominal Pain | 1 | 2017 | 44 | 0.580 |
Why?
|
| Laparotomy | 3 | 2006 | 29 | 0.580 |
Why?
|
| Spinal Cord | 5 | 2018 | 119 | 0.560 |
Why?
|
| Isothiocyanates | 3 | 2008 | 7 | 0.540 |
Why?
|
| Disease Models, Animal | 9 | 2019 | 1020 | 0.540 |
Why?
|
| Arvicolinae | 1 | 2015 | 2 | 0.530 |
Why?
|
| Ligation | 5 | 2019 | 56 | 0.520 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2006 | 40 | 0.520 |
Why?
|
| Motor Activity | 4 | 2014 | 324 | 0.500 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2020 | 742 | 0.490 |
Why?
|
| Sex Characteristics | 1 | 2015 | 173 | 0.480 |
Why?
|
| Foot Injuries | 1 | 2014 | 10 | 0.470 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 98 | 0.470 |
Why?
|
| Food | 4 | 2019 | 43 | 0.470 |
Why?
|
| Receptors, Opioid, delta | 2 | 2006 | 12 | 0.460 |
Why?
|
| Methadone | 3 | 2011 | 12 | 0.460 |
Why?
|
| Inflammation | 1 | 2017 | 529 | 0.450 |
Why?
|
| Opioid-Related Disorders | 2 | 2008 | 55 | 0.450 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2020 | 117 | 0.440 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 7 | 2015 | 14 | 0.440 |
Why?
|
| Clonidine | 3 | 2011 | 62 | 0.430 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2012 | 8 | 0.410 |
Why?
|
| Dopamine | 4 | 2015 | 232 | 0.390 |
Why?
|
| Anesthetics, Local | 1 | 2012 | 78 | 0.390 |
Why?
|
| Amygdala | 1 | 2011 | 61 | 0.360 |
Why?
|
| Globus Pallidus | 2 | 2007 | 8 | 0.350 |
Why?
|
| Cyclooxygenase 2 | 2 | 2006 | 48 | 0.340 |
Why?
|
| Infusions, Intravenous | 6 | 2011 | 100 | 0.330 |
Why?
|
| Electrodes, Implanted | 3 | 2014 | 41 | 0.310 |
Why?
|
| Enkephalins | 2 | 1998 | 10 | 0.310 |
Why?
|
| Etorphine | 2 | 1998 | 2 | 0.310 |
Why?
|
| Cannabinoids | 2 | 2020 | 41 | 0.310 |
Why?
|
| Ketorolac | 2 | 2005 | 24 | 0.300 |
Why?
|
| Substance-Related Disorders | 2 | 2000 | 128 | 0.300 |
Why?
|
| Exploratory Behavior | 2 | 2005 | 30 | 0.300 |
Why?
|
| Analgesics | 3 | 2017 | 107 | 0.290 |
Why?
|
| Mechanoreceptors | 3 | 2020 | 38 | 0.290 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2018 | 79 | 0.290 |
Why?
|
| Drug Tolerance | 1 | 2007 | 32 | 0.280 |
Why?
|
| Transferases | 1 | 2006 | 1 | 0.280 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2006 | 6 | 0.280 |
Why?
|
| Spinal Cord Diseases | 1 | 2006 | 12 | 0.280 |
Why?
|
| Cyclooxygenase 1 | 1 | 2006 | 22 | 0.280 |
Why?
|
| Cocaine-Related Disorders | 2 | 2015 | 99 | 0.270 |
Why?
|
| Spinal Cord Injuries | 1 | 2006 | 39 | 0.270 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2019 | 75 | 0.260 |
Why?
|
| Abdomen | 1 | 2005 | 43 | 0.250 |
Why?
|
| Neural Conduction | 2 | 2016 | 91 | 0.250 |
Why?
|
| Fentanyl | 4 | 2011 | 32 | 0.240 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2024 | 10 | 0.240 |
Why?
|
| Adenosine | 3 | 2011 | 58 | 0.240 |
Why?
|
| Sensory Receptor Cells | 1 | 2024 | 30 | 0.230 |
Why?
|
| Time Factors | 7 | 2017 | 2145 | 0.230 |
Why?
|
| Acetylcholine | 1 | 2004 | 48 | 0.230 |
Why?
|
| Autoradiography | 3 | 2015 | 45 | 0.220 |
Why?
|
| Nociceptors | 2 | 2020 | 41 | 0.220 |
Why?
|
| Bone Neoplasms | 1 | 2024 | 111 | 0.220 |
Why?
|
| Anesthesia | 1 | 2023 | 64 | 0.210 |
Why?
|
| Cyclohexanols | 2 | 2020 | 20 | 0.210 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 109 | 0.210 |
Why?
|
| Central Nervous System Stimulants | 1 | 2023 | 76 | 0.210 |
Why?
|
| Disease Progression | 1 | 2024 | 594 | 0.200 |
Why?
|
| Cell Proliferation | 1 | 2024 | 604 | 0.200 |
Why?
|
| Ganglia, Spinal | 2 | 2020 | 64 | 0.200 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2001 | 13 | 0.200 |
Why?
|
| Radioligand Assay | 3 | 2007 | 20 | 0.180 |
Why?
|
| Carbon Radioisotopes | 1 | 2020 | 24 | 0.180 |
Why?
|
| Microtubules | 1 | 2020 | 23 | 0.180 |
Why?
|
| Quinazolines | 1 | 2020 | 38 | 0.180 |
Why?
|
| Hydromorphone | 2 | 2011 | 5 | 0.170 |
Why?
|
| Reinforcement (Psychology) | 2 | 2000 | 2 | 0.170 |
Why?
|
| Food Preferences | 1 | 2020 | 36 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 93 | 0.170 |
Why?
|
| Sulfur Radioisotopes | 2 | 2015 | 6 | 0.170 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 163 | 0.160 |
Why?
|
| Pituitary Apoplexy | 1 | 1998 | 2 | 0.160 |
Why?
|
| Mitral Valve Prolapse | 1 | 1998 | 3 | 0.160 |
Why?
|
| Mitral Valve | 1 | 1998 | 32 | 0.160 |
Why?
|
| Papilledema | 1 | 1998 | 12 | 0.150 |
Why?
|
| Eating | 3 | 2015 | 74 | 0.150 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 1998 | 21 | 0.150 |
Why?
|
| Analysis of Variance | 3 | 2014 | 462 | 0.150 |
Why?
|
| Action Potentials | 1 | 2018 | 177 | 0.150 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2017 | 33 | 0.150 |
Why?
|
| Signal Transduction | 2 | 2024 | 680 | 0.140 |
Why?
|
| Alkylation | 2 | 2007 | 5 | 0.140 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2008 | 85 | 0.140 |
Why?
|
| Carotid Artery Diseases | 1 | 1998 | 114 | 0.140 |
Why?
|
| Binding, Competitive | 2 | 2007 | 33 | 0.140 |
Why?
|
| Triazoles | 1 | 2016 | 14 | 0.140 |
Why?
|
| Drug Synergism | 2 | 2007 | 66 | 0.140 |
Why?
|
| Pruritus | 1 | 2016 | 47 | 0.140 |
Why?
|
| Injections, Intraventricular | 3 | 2002 | 13 | 0.140 |
Why?
|
| Drug Interactions | 2 | 2006 | 77 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2018 | 222 | 0.130 |
Why?
|
| Macaca mulatta | 4 | 2020 | 305 | 0.130 |
Why?
|
| Glucose | 1 | 1997 | 174 | 0.130 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 2015 | 4 | 0.130 |
Why?
|
| Microdialysis | 3 | 2006 | 34 | 0.130 |
Why?
|
| Neuroglia | 1 | 2015 | 28 | 0.130 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2015 | 33 | 0.130 |
Why?
|
| Circadian Rhythm | 2 | 2006 | 43 | 0.130 |
Why?
|
| Carotid Artery, External | 1 | 1995 | 2 | 0.130 |
Why?
|
| Cavernous Sinus | 1 | 1995 | 2 | 0.130 |
Why?
|
| Ibogaine | 1 | 1995 | 2 | 0.130 |
Why?
|
| Phenmetrazine | 1 | 2015 | 4 | 0.130 |
Why?
|
| Dura Mater | 1 | 1995 | 14 | 0.120 |
Why?
|
| Analgesia | 1 | 2015 | 29 | 0.120 |
Why?
|
| Arteriovenous Fistula | 1 | 1995 | 18 | 0.120 |
Why?
|
| Orbit | 1 | 1995 | 19 | 0.120 |
Why?
|
| Stereotyped Behavior | 2 | 2005 | 13 | 0.120 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 29 | 0.120 |
Why?
|
| Norepinephrine | 1 | 2015 | 77 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2015 | 199 | 0.120 |
Why?
|
| Oligopeptides | 2 | 2006 | 44 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2008 | 406 | 0.110 |
Why?
|
| Cognition | 1 | 2017 | 556 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 1998 | 780 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2007 | 78 | 0.110 |
Why?
|
| Physical Stimulation | 2 | 2016 | 84 | 0.100 |
Why?
|
| Oxycodone | 1 | 2011 | 6 | 0.100 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2011 | 21 | 0.100 |
Why?
|
| Amines | 1 | 2011 | 22 | 0.100 |
Why?
|
| Pressure | 1 | 2011 | 51 | 0.090 |
Why?
|
| Humans | 9 | 2024 | 32082 | 0.090 |
Why?
|
| Reinforcement Schedule | 3 | 2003 | 57 | 0.090 |
Why?
|
| Protein Binding | 2 | 2008 | 201 | 0.090 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2008 | 3 | 0.080 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2008 | 4 | 0.080 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2008 | 4 | 0.080 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2008 | 19 | 0.080 |
Why?
|
| Nortropanes | 1 | 2008 | 2 | 0.080 |
Why?
|
| Tropanes | 1 | 2008 | 9 | 0.080 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2008 | 16 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 2008 | 68 | 0.080 |
Why?
|
| Corpus Striatum | 1 | 2008 | 60 | 0.080 |
Why?
|
| Alkylating Agents | 1 | 2007 | 5 | 0.070 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2008 | 97 | 0.070 |
Why?
|
| Microinjections | 2 | 2004 | 35 | 0.070 |
Why?
|
| Macaca fascicularis | 2 | 2020 | 434 | 0.070 |
Why?
|
| Sulfur Isotopes | 1 | 2006 | 2 | 0.070 |
Why?
|
| Theophylline | 1 | 2006 | 4 | 0.070 |
Why?
|
| Phosphatidylethanolamines | 1 | 2006 | 2 | 0.070 |
Why?
|
| Sensory Thresholds | 1 | 2006 | 28 | 0.070 |
Why?
|
| Nitrobenzenes | 1 | 2006 | 10 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2006 | 55 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2006 | 67 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2006 | 67 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 276 | 0.070 |
Why?
|
| Ileus | 1 | 2005 | 4 | 0.070 |
Why?
|
| Abdominal Muscles | 1 | 2005 | 6 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 31 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2005 | 29 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2005 | 23 | 0.060 |
Why?
|
| Female | 3 | 2024 | 19999 | 0.060 |
Why?
|
| Bupivacaine | 1 | 2005 | 50 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2006 | 3304 | 0.060 |
Why?
|
| Mice | 2 | 2024 | 2474 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2005 | 98 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2006 | 161 | 0.060 |
Why?
|
| Sucrose | 1 | 2004 | 18 | 0.060 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 2004 | 6 | 0.060 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2004 | 5 | 0.060 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2004 | 10 | 0.060 |
Why?
|
| Cholinergic Agents | 1 | 2004 | 8 | 0.060 |
Why?
|
| Immunotoxins | 1 | 2004 | 17 | 0.060 |
Why?
|
| Oxidopamine | 1 | 2003 | 6 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 72 | 0.060 |
Why?
|
| Patients | 1 | 2023 | 46 | 0.060 |
Why?
|
| Morphine Derivatives | 2 | 2005 | 2 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 725 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 244 | 0.050 |
Why?
|
| Animals, Laboratory | 1 | 2000 | 4 | 0.050 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 1 | 2000 | 5 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1998 | 1325 | 0.040 |
Why?
|
| Touch | 1 | 2020 | 37 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2000 | 175 | 0.040 |
Why?
|
| Culture Techniques | 1 | 1998 | 13 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 1998 | 14 | 0.040 |
Why?
|
| Nerve Compression Syndromes | 1 | 1998 | 9 | 0.040 |
Why?
|
| Middle Aged | 3 | 1998 | 11834 | 0.040 |
Why?
|
| Caudate Nucleus | 1 | 1998 | 25 | 0.040 |
Why?
|
| Psychology | 1 | 2018 | 24 | 0.040 |
Why?
|
| Visual Fields | 1 | 1998 | 27 | 0.040 |
Why?
|
| Optic Disk | 1 | 1998 | 11 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 1998 | 39 | 0.040 |
Why?
|
| Cerebral Angiography | 1 | 1998 | 60 | 0.040 |
Why?
|
| Motivation | 1 | 1998 | 113 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 1998 | 86 | 0.040 |
Why?
|
| Cercopithecidae | 1 | 2017 | 10 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1997 | 62 | 0.040 |
Why?
|
| Receptors, Cannabinoid | 1 | 2017 | 25 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1997 | 59 | 0.030 |
Why?
|
| Imidazoles | 1 | 2015 | 91 | 0.030 |
Why?
|
| Pyramidal Tracts | 1 | 2015 | 3 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1995 | 19 | 0.030 |
Why?
|
| Veins | 1 | 1995 | 29 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1995 | 77 | 0.030 |
Why?
|
| Proton Pumps | 1 | 2014 | 7 | 0.030 |
Why?
|
| Angiography | 1 | 1995 | 80 | 0.030 |
Why?
|
| Neurofilament Proteins | 1 | 2014 | 13 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2014 | 47 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2014 | 41 | 0.030 |
Why?
|
| Dependovirus | 1 | 2014 | 18 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 71 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2014 | 81 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1998 | 917 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 873 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2008 | 46 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2008 | 59 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 114 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 507 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 827 | 0.020 |
Why?
|
| Prosencephalon | 1 | 2005 | 5 | 0.020 |
Why?
|
| Membranes | 1 | 2005 | 10 | 0.020 |
Why?
|
| Neostriatum | 1 | 2003 | 22 | 0.010 |
Why?
|
| Electrochemistry | 1 | 1995 | 14 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1995 | 94 | 0.010 |
Why?
|
| Calcium | 1 | 1995 | 306 | 0.010 |
Why?
|